
Inhibikase Therapeutics, Inc. (NASDAQ:IKT – Free Report) – Analysts at HC Wainwright upped their Q1 2027 earnings per share (EPS) estimates for Inhibikase Therapeutics in a research report issued on Thursday, November 12th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.12) per share for the quarter, up from their previous estimate of ($0.13). HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Inhibikase Therapeutics’ current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q2 2027 earnings at ($0.11) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.09) EPS and FY2027 earnings at ($0.42) EPS.
Inhibikase Therapeutics (NASDAQ:IKT – Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01.
Get Our Latest Analysis on IKT
Inhibikase Therapeutics Price Performance
NASDAQ IKT opened at $1.52 on Monday. Inhibikase Therapeutics has a 12 month low of $1.40 and a 12 month high of $2.61. The company has a 50-day moving average of $1.90 and a 200-day moving average of $1.93. The company has a market cap of $213.21 million, a P/E ratio of -3.80 and a beta of 0.94.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Kalehua Capital Management LLC grew its position in Inhibikase Therapeutics by 118.4% during the first quarter. Kalehua Capital Management LLC now owns 3,821,890 shares of the company’s stock valued at $6,421,000 after acquiring an additional 2,071,890 shares during the period. SummitTX Capital L.P. acquired a new stake in Inhibikase Therapeutics during the first quarter worth about $2,561,000. Ally Bridge Group NY LLC acquired a new stake in Inhibikase Therapeutics during the first quarter worth about $2,226,000. Bank of New York Mellon Corp purchased a new position in shares of Inhibikase Therapeutics in the 2nd quarter worth about $615,000. Finally, Bank of America Corp DE raised its holdings in shares of Inhibikase Therapeutics by 595.3% in the 1st quarter. Bank of America Corp DE now owns 322,704 shares of the company’s stock worth $542,000 after purchasing an additional 276,293 shares during the period. Institutional investors and hedge funds own 3.81% of the company’s stock.
About Inhibikase Therapeutics
Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Parkinson’s disease and other neurodegenerative disorders. The company’s research centers on small-molecule inhibitors of Abelson tyrosine kinase, or c-Abl, a protein it is investigating for its role in neurodegeneration. Its pipeline has included IKT-148009, an oral c-Abl inhibitor being developed for Parkinson’s disease. Inhibikase is based in Atlanta, Georgia, and conducts research and development in the pharmaceutical biotechnology sector.
Recommended Stories
- Five stocks we like better than Inhibikase Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Inhibikase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibikase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
